Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-18T00:43:55.340Z Has data issue: false hasContentIssue false
  • English
  • Français

Frecuencia de la apolipoproteína E-ɛ4, en la esquizofrenia de déficit

Published online by Cambridge University Press:  12 May 2020

F. Thibaut ,
A. Van der Elst ,
D. Campion ,
C. Martin ,
B. Coron ,
S. Dollfus ,
T. H. Frebourg  and
M. Petit
F. Thibaut
Affiliation:
Unidad de Genética Molecular (Unidad INSERM EPI 9906), IFR 23, CHU de Rouen
A. Van der Elst
Affiliation:
Unidad de Genética Molecular (Unidad INSERM EPI 9906), IFR 23, CHU de Rouen
D. Campion
Affiliation:
Unidad de Genética Molecular (Unidad INSERM EPI 9906), IFR 23, CHU de Rouen
C. Martin
Affiliation:
Unidad de Genética Molecular (Unidad INSERM EPI 9906), IFR 23, CHU de Rouen
B. Coron
Affiliation:
Grupo de Investigación en Psicopatología y Esquizofrenias (JE2014), Facultad de Medicina de Rouen y Caen, Rouen, Francia
S. Dollfus
Affiliation:
Grupo de Investigación en Psicopatología y Esquizofrenias (JE2014), Facultad de Medicina de Rouen y Caen, Rouen, Francia
T. H. Frebourg
Affiliation:
Unidad de Genética Molecular (Unidad INSERM EPI 9906), IFR 23, CHU de Rouen
M. Petit
Affiliation:
Unidad de Genética Molecular (Unidad INSERM EPI 9906), IFR 23, CHU de Rouen
Get access

Resumen

Se ha encontrado que el genotipo de la apolipoproteína E (ApoE) afecta a la expresión de varios trastornos neuropsiquiátricos. Determinamos las frecuencias del genotipo de la ApoE y su relación con los síntomas negativos primarios en 61 pacientes esquizofrénicos sin déficit y 45 con déficit, y los comparamos con 98 sujetos de control. No se observaron diferencias cuando se compararon las frecuencias del genotipo o de los alelos entre los tres grupos. Nuestros datos no apoyan la existencia de un papel para la ApoE en la expresión fenotípica de la esquizofrenia.

Keywords

apolipoproteína Esíndrome de déficitesquizofrenia
Type
Artículo original
Information
European Psychiatry (Ed. Española) , Volume 7 , Issue 1 , February 2000 , pp. 41 - 44
Copyright
Copyright © European Psychiatric Association 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Amador, XF, Kirkpatrick, B, Carpenter, WT, Yale, SA, Marcinko, L.The long term stability of the definir syndrome. Schizophr Res 1996; 18: 116.CrossRefGoogle Scholar
American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edition. Washington, DC: American Psychiatric Press; 1987.Google Scholar
Andreasen, NC, Olsen, SA, Dennert, JW. Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms. Am J Psychiatry 1982; 139; 297–302.Google ScholarPubMed
Arendt, T, Schindler, C, Brükner, MK, Eschrich, K, Bigl, V, Zedlick, D, et al. Plástic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apo-lipoprotein £4 alíele. J Neurosci 1997; 17: 516–29.CrossRefGoogle Scholar
Bickeboller, H, Campion, D, Brice, A, Amouyel, P, Hannequin, D, Didierjean, O.et al. Apolipoprotein E and Alzheimer disease: genotype specific risks by age and sex. Am J Hum Genet 1996; 60: 439–46.Google Scholar
Carpenter, WT, Buchanan, RW, Kirkpatrick, B, Tamminga, C, Wood, F.Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry 1993; 50: 825–31.CrossRefGoogle ScholarPubMed
Corder, EH, Saunders, AM, Strittmatter, WJ, Schmechel, DE, Gaskell, PC, Small, GW, et al. Gene dose of apolipoprotein E type 4 alíele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921–23.CrossRefGoogle Scholar
Hixson, JE, Vernier, DTRestriction isotyping of human ApoE by gene amplification and cleavage with Hhal. Lipid Res 1990: 31: 545–8.Google Scholar
Jonsson, E, Lannfelt, L, Engvall, B, Sedvalla, G.Lack of association between schizophrenia and the apolipoprotein E epsilon 4 alíele. Eur Arch Psychiatry Clin Neurosci 1996; 246: 182–4.CrossRefGoogle Scholar
Joober, R, Rouleau, G, Fon, E, Lal, S, Palmour, R, Bloom, D, et al. Apolipoprotein E genotype in schizophrenia. Am J Med Genet 1996; 67: 235.CrossRefGoogle Scholar
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76.CrossRefGoogle Scholar
Kirkpatrick, B, Buchanan, RW, McKenney, PD, Alphs, LD, Carpenter, WT. The schedule for the déficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989; 30: 119–23.CrossRefGoogle Scholar
Lan, TH, Hong, CJ, Chen, JY, Sim, CB. Apolipoprotein E- epsilon 4 frequency in patients with schizophrenia. Biol Psychiatry 1997; 42: 225–7.Google ScholarPubMed
Marneros, A, Deister, A, Rhode, A.Validity of the negative/positive dichotomy for schizophrenic disorders under long-term conditions. Schizophr Res 1992; 7: 117–23.CrossRefGoogle ScholarPubMed
Nathan, BP, Bellosta, S, Sanan, A, Weisgraber, KH, Mahley, RW, Pitas, RE. Differential effects of apolipoprotein ε1, and ε1, on neuronal growth in vitro. Science 1997; 264: 850–2.CrossRefGoogle Scholar
Overall, JE, Gorham, DE. The brief psychiatric rating scale. Psychol Rep 1961; 10: 799–812.CrossRefGoogle Scholar
Pearlson, GD, Garbacz, DJ, Breakey Ahn, HS, Depaulo, JR. Lateral ventricular enlargement associated with persistent un-employment and negative symptoms in both schizophrenia and bipolar disorder. Psychiatry Res 1984; 12: 1–9.CrossRefGoogle Scholar
Pickar, D, Malhotra, AK, Rooney, W, Breier, A, Goldman, D.Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet 1997; 350: 930–1.CrossRefGoogle Scholar
Powchik, P, Friedman, J, Haroutunian, V, Greenberg, D, Altstein, L, Purohit, D, et al. Apolipoprotein £. in schizophrenia: study of one hundred sixteen cases with concomitant neuropathologies examination. Biol Psychiatry 1997; 42: 296–8.CrossRefGoogle Scholar
Ribeyre, JM, Dollfus, D, Lesieur, P, Ménard, JF, Petit, M.Instrument d'évaluation du syndrome déficitaire de la schizophrénie. Encephale 1994; 20: 413–9.Google Scholar
Soininen, HS, Riekkinen, PJ. Apolipoprotein E, memory and Alzheimer’s disease. Trends Neurosci 1996; 19: 224–8.CrossRefGoogle ScholarPubMed
Strittmatter, WJ, Saunders, AM, Schmechel, D, Pericak-Vance, M, Enghild, J, Salvesen, GS, et al. Apolipoprotein E: high avidity binding to amyloid and increased frequency of type 4 alíele in late onset familial Alzheimer's disease. Proc Nati Acad Sci USA 1993; 90: 1977–81.CrossRefGoogle Scholar
Thibaut, F, Ribeyre, JM, Dourmap, N, Ménard, JF, Dollfus, S, Petit, M.Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in déficit and non-deficit forms of schizophrenia. Biol Psychiatry 1988; 43: 24–30.CrossRefGoogle Scholar
Zhu, S, Nothen, MM, Uhlhass, S, Rietschel, M, Koerner, J, Lanczik, M, et al. Apolipoprotein E genotype distribution in schizophrenia. Psychiatr Genet 1996; 6:75–9.CrossRefGoogle Scholar